Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim and Bavencio in 4L MSS Metastatic Colorectal Cancer
NCT06557278Phase 2Withdrawn
- Sponsor
- Mirror Biologics, Inc.
- Start
- Nov 2026
- Primary completion
- Jun 2028
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allostim in colorectal cancer (metastatic) (mCRC), sponsored by Mirror Biologics, Inc.. Planned start Nov 2026; status: withdrawn.
02
Drugs
allostim
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT06557278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557278.